Adularia AG
Our aim is to leverage the natural metabolic interplay between the human immune system, the microbiome, and disease onset to develop molecule therapies that enhance the body’s native immune response against cancer.
Somagenetix AG
Our aim is to develop a lentiviral-based gene therapy using patient-derived stem cells from bone marrow to correct congenital gene defects.
mint & pepper
Our aim is to awaken children’s interest early and to boost teenagers’ enthusiasm for apprenticeships, research, and professional careers in STEM (Science Technology Engineering and Mathematics) fields – in German referred to as MINT (Mathematik, Informatik, Naturwissenschaften und Technologie).
MUVON Therapeutics AG
Our aim is to establish personalized treatments to help patients with Stress Urinary Incontinence regain control of their lives by offering them minimally invasive, low-risk treatments for the regeneration of skeletal muscle tissue.
ATLyphe AG
The novel bispecific T-cell engaging antibody has the potential to transform current hematopoietic stem cell transplantation practice into an immunologic precision-medicine approach.
Apersys AG
Our aim is to develop a perfusion technology to preserve and regenerate livers outside of the body to make more livers available to patients suffering from liver cancer or liver failure.
LifeMatrix Technologies AG
Our aim is to develop a unique tissue engineering technology to grow replacement tissue in the laboratory that is compatible with any patient and that regenerates and grows with the recipient.
NovaGo Therapeutics AG
Our aim is to enhance long-term axonal regeneration in the injured central nervous system and improve functional recovery.
OxyPrem AG
Our aim is to develop a specialized medical device to enable higher rate of survival in premature infants by monitoring brain oxygen levels in real time. NOAH, a specialized, high-tech medical device, has the potential to play a significant role in making this a reality.